[Skip to the guide](/#guide) [ MOTS-c specialist guide ](/) Curiosity welcome. Hype can wait. - [Guide](/) - MOTS-c briefing Before bringing MOTS-c into a care conversation # MOTS-c specialist? Start here. Curious about weight, blood sugar or energy? Let's sort out what MOTS-c is, what the research shows and what to ask about care. As of September 30, 2026, MOTS-c has no medicine approval from the US Food and Drug Administration (FDA). [Get the plain answer ](/#at-a-glance) ![A pink ceramic arch, folded lime paper and a cyan glass sphere beside a blank notebook.](/static/questions-desk.3772517ec267.webp) Room for questions. No rush. ## In this briefing - [What it is](/#at-a-glance) - [Approval & US rules](/#briefing) - [What research shows](/#evidence-brief) - [Safety gaps](/#safety-brief) - [Find & check care](/#care-brief) - [Claims to question](/#risk-brief) - [Costs & coverage](/#cost-brief) - [Questions to take](/#question-brief) - [Care words](/#source-file) At a glance ## What MOTS-c actually is MOTS-c is a peptide: a short chain of amino acids, the pieces that form proteins. Your body makes MOTS-c, and researchers have found it in blood and muscle. The instructions for making MOTS-c are in mitochondria, the parts of your cells that help produce energy. ### Does that make an injection a good idea? Finding MOTS-c in the body does not show that a lab-made shot will help you or be safe. The useful next question is what has been tested in people. The approval brief ## Can a pharmacy make MOTS-c for me? Compounding means having a pharmacist or doctor make medicine to order for a patient instead of using a ready-made product. As of September 2026, MOTS-c fails the [federal ingredient rules](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act) for a pharmacy making medicine to order for a named patient. A doctor’s prescription does not remove those ingredient limits. As of September 30, 2026, [FDA’s list of withdrawn requests](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) includes the request to allow MOTS-c in pharmacy-made medicines. Here, “withdrawn” means the people who submitted the request took it back. Taking the request back does not give a pharmacy permission to make MOTS-c medicines. Your state’s pharmacy board is the public body that gives pharmacies permission to operate. If a clinic claims an exception, ask for it in writing and have your state’s pharmacy board check it before agreeing to treatment. ### Did the panel meeting allow treatment? FDA staff advised against adding MOTS-c to the allowed list before the July 2026 panel meeting. The panel discussed MOTS-c in July 2026, but [FDA’s meeting page](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) still had no published vote record as of September 30, 2026. We cannot tell you the vote result from that page. Under the rules checked as of September 2026, even a yes vote would not let a pharmacy start making MOTS-c medicines. A panel vote only advises FDA; changing the allowed-ingredient list requires a formal FDA rule change. The evidence brief ## What the research can tell you ### Mice are a starting point In [Lee’s mouse study](https://pubmed.ncbi.nlm.nih.gov/25738459/), published in 2015, treated mice gained less weight and handled sugar better on a high-fat diet. The mouse results do not show that MOTS-c helps people. Measuring the MOTS-c already in someone’s blood is different from testing a MOTS-c treatment. ### The finished study tested a changed version A completed human study listed on [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03998514) tested CB4211, a substance made by changing MOTS-c. The company developing CB4211 reported its own findings; they had not appeared in a medical journal as of September 30, 2026. CB4211 is different from MOTS-c itself, so that study cannot tell you how a MOTS-c shot would work. ### A MOTS-c study has no results yet A [public study entry](https://clinicaltrials.gov/study/NCT07505745) describes a MOTS-c study in adults with extra weight that began in February 2026. As of September 30, 2026, that entry said the study was still inviting people to join and had no results posted. ### So what can I expect? As of September 30, 2026, no published study showed the results of giving MOTS-c itself to people. Weight loss, more stamina and slower ageing are not proven MOTS-c benefits in people. The safety brief ## The gaps in safety knowledge [FDA’s MOTS-c review](https://www.fda.gov/media/193347/download) found no human studies showing whether MOTS-c is safe. FDA also found no animal tests for damage to genes (the instructions inside cells), harm during pregnancy or cancer risk. That is missing information, not evidence that MOTS-c causes those harms. FDA raises a concern that injected MOTS-c could trigger an immune reaction, meaning the body’s defences treat it as an invader. This is a possible risk; studies have not shown how often it might happen in people. ### Pregnant or breastfeeding? As of September 2026, there is no official MOTS-c medicine label listing who must avoid it, and its effects during pregnancy or breastfeeding are unknown. Bring that question into a care discussion before considering a treatment. ### Competing in sport? As of September 2026, MOTS-c is banned under the 2026 list from the [World Anti-Doping Agency](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf), both during and outside competition. ### If a treatment has already caused a problem [MedlinePlus](https://medlineplus.gov/ency/article/000844.htm) names breathing trouble and a swollen face or tongue as signs of a severe allergic reaction. Severe symptoms call for emergency care. A patient can report a medicine problem through [FDA MedWatch](https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program), the agency’s free reporting service. The care brief ## Start with your concern, then check the clinician The word clinician means a health professional who evaluates people and provides treatment. A care discussion can happen at a clinic in person or through telehealth, using video, phone calls or exchanges online. Lead with what is bothering you: weight changes, blood sugar or energy. Ask which tests or established treatments fit that concern. Be ready to discuss options beyond MOTS-c. - Write down what changed, when it began and what you hope to improve. - Bring a list naming each medicine and supplement you take. - Add questions about pregnancy, breastfeeding or past reactions. ### Check the person Ask for the clinician's full name and licence details. State medical boards give doctors permission to practise and publish whether a doctor’s licence is current. They also publish public records of action taken against doctors for breaking professional rules. Open the board for your state through the [medical board directory](https://www.fsmb.org/contact-a-state-medical-board/), then search the doctor’s name. As of September 2026, [US health department guidance](https://telehealth.hhs.gov/licensure/getting-started-licensure) says online clinicians need permission to practise in the state you are physically in during your visit. If the clinician claims an exception, ask your state’s medical board to check it. A current licence does not tell you how skilled a doctor is. ### Check the pharmacy too If medicine is proposed, ask who would make and supply it. [FDA’s pharmacy lookup](https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy) sends you to your state’s licence records. A pharmacy licence means the business has permission to operate; it does not show that every product it supplies is appropriate. Keep the pharmacy's name with your care notes. ### What happens during online care? The [Federation of State Medical Boards](https://www.fsmb.org/siteassets/advocacy/policies/fsmb-workgroup-on-telemedicineapril-2022-final.pdf) says clinicians must be able to ask you more questions after you fill in an online form. That group advises the state bodies that license doctors. It advises against basing treatment solely on a form’s fixed questions and answers. The group’s advice is guidance, not state law. If your care needs a test or an examination in person, the advice says the clinician must arrange it or refer you. Ask how follow-up questions, tests and visits in person are handled. The risk brief ## Claims that deserve a pause ### A lab label offered as treatment A label saying “for research use only” claims the product is for lab research, rather than treating people. The label does not mean “tested in patients”. A study in people needs its own evidence; a bottle label cannot provide that. In letters checked as of September 2026, FDA said that this label does not excuse marketing a product as treatment for people. If a clinic offers such a product, ask for the product and pharmacy names in writing and have your state’s pharmacy board check the offer. ### Badges and codes do not prove FDA approval An ad may say [“FDA registered”](https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved): that refers to a business being recorded with the agency. A National Drug Code (“NDC number”) identifies a product in an FDA list. As of September 2026, neither registration nor a directory listing means FDA has approved the product. Ask what the badge or number actually tells you about the proposed medicine. ### A menu with no health check The Federation of State Medical Boards says in its [May 2026 guidance](https://www.fsmb.org/siteassets/advocacy/policies/guidance-on-recent-trends-in-prescribing-and-dispensing-adopted.pdf) that a treatment menu alone is not a proper health assessment. This is the group’s advice; the rules your state enforces come from your state’s own laws. Ask who will discuss your health and answer your questions before any treatment is chosen. The cost brief ## What it costs—and what to get in writing As of September 30, 2026, no FDA-approved MOTS-c medicine exists, so there is no published price from an approved product’s maker. This guide has no reliable price range for MOTS-c care. A price in an advertisement does not show that MOTS-c is approved, works in people or meets pharmacy ingredient rules. Ask for the full bill in writing before agreeing to care: the visit, tests, any medicine and later visits. For a monthly plan, ask for the total over its full length. **The visit** Is the fee paid once, or every month? Will I pay for the visit even if I decide against treatment? **Tests** Which tests do I need and why? Will I pay the lab separately? **Follow-up** What is included, and what creates another charge? **Any proposed medicine** Which medicine is proposed? Who will make it, and what does it add to the bill? ### What about insurance? Treat the visit, lab work and medicine as separate coverage questions. Ask your insurer what it pays for and whether it must agree before care. Keep the answer in writing. Before any monthly plan, ask what happens if you stop or no medicine is prescribed. Keep this bit ## Take these questions to a care visit - Which health concern are we trying to address? - What evidence in people supports this option for that problem? - Is this a medicine with FDA approval or one made to order? Does the label instead say “for research use only”? - Will you name the product and pharmacy in writing so I can ask my state’s pharmacy board to check the offer? - Which clinician and pharmacy can I check in public licence records? - What will the visit, tests and follow-up cost, including if treatment is declined? - How can I reach the clinician with questions after the visit? A useful answer names the evidence, the limits and the next step. You do not have to settle the whole decision today. The word brief ## Care words, in plain language **Peptide** A short chain of amino acids, the pieces that form proteins. **Compounding** Preparing medicine for a patient’s particular needs instead of supplying a ready-made product. **Telehealth** Care through video, phone calls or exchanges online. **Clinical trial** A study that tests a treatment in people. MOTS-c Specialist guides you through care questions; we do not run a clinic or sell any products. [Plain-text copy](/index.md) [Back to the start ](/#guide)